Petros Pharmaceuticals Inc
NASDAQ:PTPI 4:00:00 PM EDT
| Market Cap (Intraday) | 4.68M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.75 |
| 50-Day MA | $1.30 |
| 200-Day MA | $1.77 |
Petros Pharmaceuticals Inc Stock, NASDAQ:PTPI
1185 Avenue of the Americas, 3rd floor, New York, New York 10036
United States of America
Phone: +1.973.242.0005
Number of Employees: 21
Description
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.